•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Imexpharm aims for growth in 2026 with a focus on expanding R&D capacity and high-tech manufacturing, in a context where the pharmaceutical industry faces demands for self-reliance in supply and alignment with international standards. The strategy is being implemented consistently, anchored by a portfolio of nearly 160 R&D projects that can be manufactured immediately on the existing four-plant system. The company is also initiating research, review, and selection of a portfolio of nearly 150 products for a new factory in Cat Khanh industrial park, with nearly 50% being medications for chronic diseases. In the first quarter of 2026, driven by EU-GMP production and domestic market understanding, Imexpharm posted revenue of VND 629 billion and pre-tax profit of VND 103 billion, up 8% year-on-year. Based on this, Imexpharm aims to maintain stable growth with continued double-digit profit growth, with projected revenue of VND 3,200 billion. From EU-GMP to global supply chains: Vietnam's pharmaceutical sector's strategic shift. Global geopolitical conflicts have highlighted the importance of securing drug supply. The World Health Organization notes that geopolitical volatility has affected global pharmaceutical supply chains, spurring a push to increase domestic production capacity and self-reliance, especially for high-technology products. The government targets that by 2030, domestically produced medicines will meet about 80% of domestic needs, with a higher share of high-technology products. Globally, IQVIA Institute's Global Medicine Use Trends 2026 projects that between 2026 and 2030 the global pharmaceutical market will grow at a more moderate pace, with a CAGR of about 5-8%, as mature economies gradually saturate and cost-control pressures rise. Emerging markets, including Vietnam, continue to be key growth drivers for the global pharma industry, with demand expanding as GDP per capita rises and the disease burden shifts. To address this, high-standard manufacturing capabilities such as EU-GMP—exemplified by Imexpharm with 12 production lines—are not only a competitive edge but also open opportunities to participate more deeply in global supply chains and achieve self-reliance in supply. Notably this year marks Imexpharm's 11th year with EU-GMP, underscoring the company's extensive experience and proficiency in EU-GMP practices, setting it apart from other EU-GMP producers. 2026: Imexpharm proactively facing opportunities and challenges. Leadership identifies a clear mix of opportunities from macro growth, improved household incomes, and policies prioritizing domestic pharma development; yet rising competition from EU-GMP-invested players and new governance requirements, along with price competition from imported drugs, could affect margins. Cạnh tranh gia tăng là tất yếu nhưng Imexpharm vẫn duy trì những lợi thế bao gồm: tối ưu hóa chi phí sản xuất khi nhà máy đã khấu hao trong 10 năm qua. Ban lãnh đạo Imexpharm nhấn mạnh: “10 năm EU-GMP” khẳng định năng lực vượt trội và khó sao chép của đội ngũ Imexpharm trong nghiên cứu, sản xuất và quản lý chất lượng, để mỗi viên thuốc tới tay bệnh nhân đều mang lại một sự yên tâm tuyệt đối về an toàn và hiệu quả điều trị.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
